Tip os
Log ind
Jakob-Riis-2-NovoNordisk-EVP-China-Pacific-Marketing-hires.jpg
Foto: Novo Nordisk/PR

Novo’s US boss wants to kick Tresiba sales into gear

Top picks in English:

Novo Nordisk has not captured as much of the lucrative diabetes market in the US as it had hoped. Blockbuster hopeful Tresiba holds the key to success, but it’s easier said than done.


BY STEFAN SINGH KAILAY & BENJAMIN WERNER CHRISTENSEN, FINANS.DK
Offentliggjort 13.09.16 kl. 15:30

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Here is what Danish drug companies pay their workers

Løn Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Former William Demant CFO joins German rehab giant

Top picks in English:

A former Chief Financial Officer from hearing device maker William Demant takes over as finance chief for one of the biggest rehabilitation care companies in the world.

Novo A/S invests billions in laboratory company

Top picks in English:

For the third time, Novo A/S invests in Synlab, Europe’s biggest company for laboratory analyses. Previously, Novo A/S has not wanted to disclose the amount invested. But this time, the investment sum is revealed and it amounts to billions of Danish kroner.

Diabetes combo from Sanofi and Zealand gets thumbs up

Top picks in English:

France’s Sanofi and its Danish biotech partner Zealand Pharma has been given a positive recommendation for European approval of a new combination treatment against diabetes.

Lundbeck Foundation company goes public

Top picks in English:

Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.

Lene Skole: Chose a career over a House & Garden home

Top picks in English:

The Lundbeck Foundation’s CEO, Lene Skole, is calling for better domestic help for Danish families, so everyone – even women – are able to attend to their careers and go for top management positions. She made a clear choice early on, which has helped propel her to the top.

Forsiden lige nu

De første studieresultater: Overvægtige taber sig med Novo Nordisks fedmehåb

COLOURBOX524861.JPG Medicinal & Biotek:

Novo Nordisk fører an i jagten på at udvikle medicin, som kan smelte kilo af overvægtige kroppe. Spritnye resultater for GLP-1-analogen Semaglutid viser de første gode takter for medicinalkoncernens næste fedmehåb. (opdateret)

MedWatch-indeks: Gode nyheder giver overvægt af grønt

Medicinal & Biotek:

Studieresultater og medvind fra FDA såvel som EMA sender det danske life science-indeks op i en overvægt af grønne tal, selv ikke den dårligste nyhed formår at sende det ansvarlige selskab i rødt.

Lundbeck-direktør: Jeg var klar over, at FDA så det på en anden måde

Medicinal & Biotek:

Om Lundbeck vil forsøge en tredje gang at få udvidet indlægssedlen på antidepressivet Trintellix i USA er endnu uvist, siger forskningsdirektør Anders Gersel Pedersen for hvem, nattens afslag fra FDA ikke var en fuldstændig overraskelse.

Novo står til længe ventet labelopdatering i Europa

Medicinal & Biotek:

Novo Nordisk er godt på vej til at kunne medtage data fra det vigtige hjerte-kar-studie Leader i indlægssedlen for diabetesblockbusteren Victoza i Europa efter en positiv anbefaling fra CHMP.

Amerikanere godkender blodkræftmiddel fra Roche

Medicinal & Biotek:

Roches storsælgende kræftmiddel Rituxan har af de amerikanske lægemiddelmyndigheder fået grønt lys til tre former for blodkræft.

FDA puster til patentstrid med ny godkendelse

Medicinal & Biotek:

De amerikanske lægemiddel-myndigheder har godkendt den første behandling af sjælden sygdom, der kan administreres af patienten selv. Det sker midt i patentslagsmål med midlet som centrum.

ANNONCE
ANNONCE


ANNONCE